Download Files:

TP-064

$42$990

Products Details

Product Description

– TP-064 is a potent and selective proteinarginine methyltransferase 4 (PRMT4; CARM1) inhibitor (IC50 <10 nM). TP-064 inhibits dimethylation of BAF155 (IC50 of 340 nM) and MED12 (IC50 of 43 nM). TP-064 is inactive against the other family members except for PRMT6 (IC50 of 1.3 μM). TP-064 has anticancer activities[1].

Web ID

– HY-114965

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C28H34N4O2

References

– [1]Kazuhide Nakayama, et al. TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget. 2018 Apr 6;9(26):18480-18493.|[2]Yiheng Zhang, et al. PRMT4 inhibitor TP-064 inhibits the pro-inflammatory macrophage lipopolysaccharide response in vitro and ex vivo and induces peritonitis-associated neutrophilia in vivo. Biochim Biophys Acta Mol Basis Dis. 2021 Jul 24;1867(11):166212.

CAS Number

– 2080306-20-1

Molecular Weight

– 458.60

Compound Purity

– 98.35

SMILES

– O=C(C1=CC=CC(OC2=CC=CC=C2)=C1)N(CC3=CC(C4CCN(CC4)CCNC)=NC=C3)C

Clinical Information

– No Development Reported

Research Area

– Cancer; Inflammation/Immunology

Solubility

– DMSO : 125 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : ≥ 50 mg/mL

Target

– Histone Methyltransferase

Isoform

– PRMT4;PRMT6

Pathway

– Epigenetics

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.